Effect of intrapartum hyoscine butylbromide and sodium bicarbonate on spontaneous vaginal birth in nulliparous women after induction of labour (SAINT): multicentre randomised placebo controlled factorial trial
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: OBJECTIVE: To determine whether intrapartum hyoscine butylbromide, sodium bicarbonate, and their combination increase the rate of spontaneous vaginal birth in nulliparous women undergoing induction of labour. DESIGN: Multicentre, randomised, double blind, placebo controlled, 2×2 factorial phase 3 trial (SAINT). SETTING: 11 Norwegian hospitals providing comprehensive obstetric care. PARTICIPANTS: Nulliparous women aged 18-50 years with a singleton live fetus in cephalic presentation at term with an indication for induction of labour. INTERVENTIONS: Participants were randomly assigned (1:1:1:1) to oral sodium bicarbonate (4×1 g per dose) plus intravenous hyoscine butylbromide (20 mg per dose), oral sodium bicarbonate plus intravenous placebo, oral placebo plus intravenous hyoscine butylbromide, or double placebo. The investigational medicinal product was administered at the onset of active labour and repeated every four hours to a maximum of three doses. MAIN OUTCOME MEASURE: Spontaneous vaginal birth (no instrumental or caesarean delivery). RESULTS: Between 4 January 2023 and 29 January 2025, 3094 nulliparous women were randomised, and 2963 comprised the full analysis set. Spontaneous vaginal birth occurred in 57% (422/741) in the bicarbonate plus hyoscine butylbromide arm, 61% (445/734) in the bicarbonate arm, 61% (449/741) in the hyoscine butylbromide arm, and 56% (422/747) in the double placebo arm. Marginal risk differences for spontaneous vaginal birth compared with double placebo were -0.2 (95% confidence interval -5.1 to 4.7; P=0.93) percentage points for combined treatment, 3.1 (-1.7 to 8.0; P=0.21) percentage points for bicarbonate, and 4.0 (-0.8 to 8.9; P=0.10) percentage points for hyoscine butylbromide. Serious adverse events were similar between groups, and no treatment related serious morbidity or deaths were observed. CONCLUSIONS: No clear evidence was found that intrapartum hyoscine butylbromide, sodium bicarbonate, or their combination increased spontaneous vaginal birth compared with placebo. Although small beneficial effects cannot be excluded, the findings do not support routine intrapartum use of either agent to facilitate spontaneous vaginal birth after induction of labour. TRIAL REGISTRATION: European Clinical Trials Database (EudraCT; 2021-000392-37); EU Clinical Trials Information System (CTIS; EU CT number 2024-511848-55-00); ClinicalTrials.gov (NCT05719467).
Source: BMJ
Authors: Trond Melbye Michelsen, Lisa Tangnes Leeves, Aslak Vimme Solhoff, Nina Gunnes Nilsen, Anne Molne Kjøllesdal, Åse Torunn R Pettersen, Elisabeth Magnussen, Ragnar Kvie Sande, Jørg Kessler, Tonje Lippert, Marte Ween-Velken, Katrine Sjøborg, Camilla Haavaldsen, Anne Flem Jacobsen, Ingvil Krarup Sørbye
Institutions: Oslo University Hospital, University of Oslo, Sørlandet Sykehus, Vestre Viken Hospital Trust, University Hospital of North Norway, Norwegian University of Science and Technology, St Olav's University Hospital, Stavanger University Hospital, University of Bergen, Haukeland University Hospital, Østfold Hospital Trust, Akershus University Hospital
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7236011336
